Wire
Myriad Genetics Secures Japanese Regulatory Approval For Prostate Cancer Diagnostic Test
Myriad Genetics (MYGN) said Tuesday the Japanese health ministry authorized its companion diagnostic tool for patients with prostate cancer.The regulatory clearance allows medical professionals to use the screening test to help guide treatment with the medication olaparib, the company said.The screening tool can now be ordered to assess specific genetic mutation statuses for breast, ovarian, and prostate cancers, Myriad Genetics said.Shares of the company were up over 2% in Tuesday trading.Price: $4.67, Change: $+0.08, Percent Change: +1.63%
$MYGN
